



than-expected tiles volume

SOMANY CERAMICS

Near-term pain, medium-term outlook positive

**Building Materials** 

03 August 2024

Utkarsh Nopany research@bobcaps.in

# Maintain BUY and TP of Rs 900 on strong earnings growth prospects with improvement in ROE profile and reasonable valuations

Misses our revenue/EBITDA estimate by 2%/8% mainly due to lower-

Maintained guidance of low double-digit volume growth and margin

improvement of 1.0%-1.5% for FY25, despite poor show in Q1

**Weak quarter:** SOMC reported a weak Q1FY25 result as it misses our estimates (Revenue: -1.9%; EBITDA: -8.4%; APAT: -14.5%) mainly due to lower-than-expected tiles sales volume (-0.9% YoY vs +3.0% estimated). Overall, SOMC revenue/EBITDA/APAT fell by 1.4%/3.2%/35.7% YoY in Q1FY25.

**Key highlights:** SOMC tiles volume was down 0.9% YoY, but it grew at 5.5% on a 5Y CAGR basis in Q1FY25. Despite lower tiles realisation (-2.0% YoY), gross margin improved by 407bps YoY to 57.1% in Q1FY25 due to better mix (GVT tiles share up 400bps to 37%) and lower input costs. However, EBITDA margin was down 16bps YoY to 8.5% in Q1FY25 due to higher employee cost (+14.1%) and negative operating leverage. Net debt rose slightly from Rs 2.6bn in Mar'24 to Rs 2.7bn in Jun'24 due to higher inventory (from 43 days in Q4FY24 to 59 days in Q1FY25) as well as debtors (from 41 days in Q4FY24 to 43 days in Q1FY25).

**Optimistic guidance:** The company has maintained its guidance of growing volume at a low double-digit rate and improving EBITDA margin by 1.0%-1.5% in FY25 – which we believe is at a risk based on the poor show in Q1 and expectation of demand recovery from Q4FY25. Over the medium term, the company targets to grow its revenue at a double-digit rate over the next three to four years. Max plant operated at a loss in Q1FY25 due to low capacity utilisation (at 35-37%), but the operating margin from this plant is expected to steadily improve over the next few quarters with rise in capacity utilisation. The company has no major capex plan and has put its Nepal plant on hold due to unfavourable market dynamics.

**Maintain BUY and TP of Rs 900:** We maintain our BUY rating on the stock as we see (a) strong earnings growth prospects (EPS to log 20% CAGR over FY24-FY27E) along with improvement in ROE profile (from 11.4% in FY24 to 15.1% in FY27E); and (b) reasonable valuation (trades at 25.7x on 1Y forward P/E vs. 5Y average of 24.0x). We cut our EPS estimates by 4.6%/4.3% for FY25E/FY26E based on weak Q1, but we have kept our TP unchanged at Rs 900 as we roll forward valuations from Mar'26 to Jun'26. Our target P/E remains unchanged at 25x.

## Key changes

	Target	Rating				
	<►	<►				
Ticker/	Price	SOMC IN/Rs 748				
Market	сар	US\$ 366.3mn				
Free float		45%				
3M ADV		US\$ 1.1mn				
52wk high/low		Rs 873/Rs 561				
Promo	ter/FPI/DII	55%/2%/24%				
-						

Source: NSE | Price as of 2 Aug 2024

## Key financials

Y/E 31 Mar	FY24A	FY25E	FY26E
Total revenue (Rs mn)	25,914	26,621	29,605
EBITDA (Rs mn)	2,532	2,612	2,962
Adj. net profit (Rs mn)	983	1,035	1,417
Adj. EPS (Rs)	24.0	25.3	34.6
Consensus EPS (Rs)	24.0	32.4	41.7
Adj. ROAE (%)	11.4	11.8	14.4
Adj. P/E (x)	31.2	29.6	21.6
EV/EBITDA (x)	11.0	10.7	9.7
Adj. EPS growth (%)	37.0	5.3	36.9
Source: Company, Bloomberg, BOB	CAPS Research		

## Stock performance



Source: NSE





Particulars (Rs mn)	Q1FY25	Q1FY24	YoY (%)	Q4FY24	QoQ (%)
Total operating income	5,786	5,865	(1.4)	7,375	(21.6)
Raw-Material expense	2,485	2,757	(9.9)	3,561	(30.2)
Gross Profit	3,301	3,108	6.2	3,815	(13.5)
Employee expense	868	760	14.1	867	0.1
Energy costs	1,276	1,189	7.3	1,399	(8.8)
Other expense	668	653	2.3	754	(11.4)
EBITDA	490	506	(3.2)	795	(38.4)
D&A	192	168	14.3	193	(0.7)
EBIT	298	338	(11.9)	602	(50.5)
Interest cost	135	112	20.9	134	0.5
Non-operating expense/(income)	(21)	43	(149.2)	(49)	(57.0)
PBT	184	184	(0.2)	516	(64.4)
Tax	61	58	4.8	177	(65.5)
Reported PAT	123	126	(2.5)	339	(63.8)
Adjusted PAT	123	191	(35.7)	287	(57.2)
As % of net revenues			(bps)		(bps)
Gross margin	57.1	53.0	407	51.7	534
Employee cost	15.0	13.0	204	11.8	324
Energy cost	22.1	20.3	178	19.0	309
Other cost	11.5	11.1	42	10.2	132
EBITDA margin	8.5	8.6	(16)	10.8	(231)
Tax rate	33.3	31.7	158	34.3	(104)
APAT margin	2.1	3.3	(113)	3.9	(176)

# Fig 1 – Quarterly performance – Consolidated

Source: Company, BOBCAPS Research

# Fig 2 – Segment financials

Particulars	Q1FY25	Q1FY24	YoY (%)	Q4FY24	QoQ (%)
Tiles revenue (Rs mn)	4,972	5,121	(2.9)	6,115	(18.7)
- Own	1,726	2,107	(18.1)	2,100	(17.8)
- JV	2,037	1,759	15.8	2,234	(8.8)
- Outsourced	1,210	1,255	(3.6)	1,780	(32.1)
Non-tiles revenue (Rs mn)	787	720	9.2	979	(19.6)
Bathware	605	579	4.6	796	(23.9)
Adhesives	181	142	27.8	183	(0.8)
Tiles sales volume (MSM)	15.6	15.7	(0.9)	18.9	(17.6)
- Own	5.5	6.5	(14.5)	6.7	(17.2)
- JV	6.1	5.2	16.6	6.7	(9.1)
- Outsourced	3.9	4.0	(1.8)	5.5	(28.6)
Tiles Realisation (Rs/sqm)	320	326	(2.0)	324	(1.3)
- Own	312	325	(4.2)	314	(0.7)
- JV	334	336	(0.7)	333	0.3
- Outsourced	309	315	(1.9)	325	(4.8)
Blended EBITDA per unit (Rs/sqm)	31.5	32.2	(2.4)	42.1	(25.2)

Source: Company, BOBCAPS Research




# Earnings call highlights


- Tile demand: Tile industry demand was quite sluggish in Q1FY25 due to muted environment and which got aggravated further due to extreme heatwave conditions and general elections. The industry demand in the month of Jul remained weak, but it has been better than May and Jun. Demand is expected to improve from the end of Q3FY25. The domestic tile industry market is expected to grow at sub-5% in FY25. However, the tile industry is expected to grow at a healthy rate over the next three to four years due to the uptick in real estate activity in metro cities.
- Guidance: SOMC maintained its volume growth guidance of low double-digit rate with improvement in EBITDA margin of 1.0-1.5% for FY25. The company targets growing its revenue at double-digit CAGR for the next three to four years.
- Product mix: GVT share rose 400bps YoY to 37% in Q1FY27 and is expected to improve further to ~50% over the next couple of years.
- Max plant reported an operating loss in Q1FY25 as it operated at low utilisation (35-37%). The plant is expected to reach breakeven point at 60-65% rate. The operating margin from this plant is expected to steadily improve over the next few quarters with rise in capacity utilisation.
- Sales mix: The share of tile sales to government infra project is 11%-12% for Q1FY25.
- **Bathware:** Revenue grew by 4.6% YoY in Q1FY25.
- Brand spend as a proportion of sales was relatively stable at 2.0% in Q1FY25, but the company plans to increase it to 2.75-3.0% in FY25.
- Capex: SOMC has no major capex plan for FY25. The company has put its Nepal project on hold at the moment due to unfavourable demand-supply fundamentals (where the local demand has fallen from 18-20msm to 11-12msm and capacity has risen upto 20msm). The company may plan to come up with a growth capex plan in the near future as its existing capacity is expected to be fully utilised over the next 18 months.



### Fig 3 – SOMC's tile volumes de-grew by 0.9% YoY, but it was up 5.5% on a 5Y CAGR basis in Q1FY25




### Fig 5 – Gross margin improved sharply in Q1FY25 due to improved product-mix and low raw material prices



Source: Company, BOBCAPS Research

# Fig 7 – EPS projected to clock a healthy 20% CAGR over FY24-FY27E...



## Fig 4 – SOMC product mix improved due to rising share of GVT sales volume






Fig 6 – EBITDA margin was slightly down in Q1FY25 on higher employee cost and negative operating leverage




## Fig 8 – ... on expectations of reasonable volume growth assumption of 8.4% CAGR over FY24-FY27E...






# Fig 9 – ... and improvement in EBITDA margin due to better mix and operating leverage



# Fig 10 – ROE projected to improve on healthy earnings and completion of major growth capex





# Valuation methodology

We maintain our BUY rating on the stock as we see (a) strong earnings growth prospects (EPS to log 20% CAGR over FY24-FY27E) along with improvement in ROE profile (from 11.4% in FY24 to 15.1% in FY27E); and (b) reasonable valuation (trades at 25.7x on 1Y forward P/E vs. 5Y average of 24.0x).

We cut our EPS estimates by 4.6%/4.3% for FY25E/FY26E based on weak Q1, but we have kept our TP unchanged at Rs 900 as we roll forward our valuation from Mar'26 to Jun'26. Our target P/E remains unchanged at 25x. We have introduced FY27 estimates.

### Fig 11 – Revised estimates

Consolidated (Rs bn)	New		Old		Change (%)	
Consolidated (RS bil)	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E
Total operating income	26.6	29.6	27.0	30.0	(1.4)	(1.3)
EBITDA	2.6	3.0	2.7	3.2	(4.8)	(6.6)
EBITDA Margin (%)	9.8	10.0	10.2	10.6	(35bps)	(56bps)
EPS (Rs)	25.3	34.6	26.5	36.1	(4.6)	(4.3)

Source: BOBCAPS Research






Fig 13 – Key assumptions

Particulars (%)	FY22A	FY23A	FY24A	FY25E	FY26E	FY27E
Tile Volume Growth	16.1	10.4	5.2	5.8	10.0	9.3
Tile Realisation Growth	10.0	6.0	(2.5)	(1.8)	0.4	0.0
Tile Revenue Growth	27.7	17.0	2.5	3.9	10.4	9.3
Non-Tile Revenue Growth	23.4	23.8	18.2	13.5	16.0	16.0
Non-Tile Revenue Share	10.9	11.5	13.0	14.0	14.6	15.4

Source: Company, BOBCAPS Research



# Key risks

Key downside risks to our estimates are:

- weak tiles exports from India on a sustained basis,
- poor offtake of the recently launched large slab GVT tiles, and
- below-expected recovery in operating margin.

# Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
Apollo Pipes	APOLP IN	0.3	632	650	HOLD
Astral	ASTRA IN	6.8	2,130	2,200	HOLD
Century Plyboards	CPBI IN	1.9	713	700	HOLD
Cera Sanitaryware	CRS IN	1.4	8,939	7,700	HOLD
Finolex Industries	FNXP IN	2.3	310	325	HOLD
Greenlam Industries	GRLM IN	0.9	583	560	HOLD
Greenpanel Industries	GREENP IN	0.5	355	365	HOLD
Greenply Industries	MTLM IN	0.6	376	400	HOLD
Hindware Home Innovation	HINDWARE IN	0.4	437	600	BUY
Kajaria Ceramics	KJC IN	2.8	1,461	1,450	HOLD
Prince Pipes & Fittings	PRINCPIP IN	0.8	635	750	HOLD
Somany Ceramics	SOMC IN	0.4	748	900	BUY
Supreme Industries	SI IN	7.8	5,163	5,400	HOLD

Source: BOBCAPS Research, NSE | Price as of 2 Aug 2024



# Financials

Income Statement					
Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25E	FY26E	FY27E
Total revenue	24,785	25,914	26,621	29,605	32,655
EBITDA	1,889	2,532	2,612	2,962	3,362
Depreciation	679	725	784	813	839
EBIT	1,211	1,807	1,828	2,149	2,523
Net interest inc./(exp.)	(404)	(465)	(500)	(380)	(380)
Other inc./(exp.)	145	106	84	124	124
Exceptional items	2	0	0	0	0
EBT	950	1,449	1,412	1,893	2,266
Income taxes	259	434	377	476	570
Extraordinary items	22	21	0	0	0
Min. int./Inc. from assoc.	46	(25)	1	1	1
Reported net profit	715	969	1,035	1,417	1,697
Adjustments	28	14	0	0	0
Adjusted net profit	743	983	1,035	1,417	1,697

Balance Sheet

FY23A	FY24A	FY25E	FY26E	FY27E
3,777	5,593	5,776	6,424	7,086
1,277	1,288	1,288	1,288	1,288
52	48	49	55	61
4,884	3,351	3,380	3,504	3,630
1,176	1,229	1,229	1,229	1,229
85	82	82	82	82
7,785	7,119	8,023	9,261	10,742
8,945	8,330	9,234	10,472	11,954
20,111	19,838	20,957	22,972	25,247
1,864	855	1,897	2,282	3,004
2,683	3,372	3,464	3,853	4,249
3,915	3,466	3,617	4,111	4,546
532	522	539	599	661
0	0	0	0	0
9,647	10,750	10,567	10,254	9,914
473	96	96	1,096	2,096
504	458	458	458	458
84	81	81	81	81
409	238	238	238	238
20,111	19,838	20,957	22,972	25,247
	1,277 52 4,884 1,176 85 7,785 8,945 <b>20,111</b> 1,864 2,683 3,915 532 0 9,647 473 504 84 409	3,777 5,593   1,277 1,288   52 48   4,884 3,351   1,176 1,229   85 82   7,785 7,119   8,945 8,330   20,111 19,838   1,864 855   2,683 3,372   3,915 3,466   532 522   0 0   9,647 10,750   473 96   504 458   84 81   409 238	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$

### Cash Flows

00311110103					
Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25E	FY26E	FY27E
Cash flow from operations	1,566	3,893	2,160	2,197	2,567
Capital expenditures	(1,515)	(1,406)	(600)	(1,500)	(1,500)
Change in investments	0	0	0	0	0
Other investing cash flows	121	86	84	124	124
Cash flow from investing	(1,394)	(1,320)	(516)	(1,376)	(1,376)
Equities issued/Others	0	(3)	0	0	0
Debt raised/repaid	118	(1,533)	29	123	126
Interest expenses	(404)	(465)	(500)	(380)	(380)
Dividends paid	(132)	(125)	(131)	(180)	(215)
Other financing cash flows	70	(1,482)	2	2	2
Cash flow from financing	(348)	(3,607)	(601)	(435)	(468)
Chg in cash & cash eq.	(177)	(1,034)	1,043	386	722
Closing cash & cash eq.	1,864	855	1,897	2,282	3,004

Per Share					
Y/E 31 Mar (Rs)	FY23A	FY24A	FY25E	FY26E	FY27
Reported EPS	16.8	23.6	25.3	34.6	41.4
Adjusted EPS	17.5	24.0	25.3	34.6	41.4
Dividend per share	3.0	3.0	3.2	4.4	5.
Book value per share	185.4	175.6	197.7	227.9	264.
Valuations Ratios					
Y/E 31 Mar (x)	FY23A	FY24A	FY25E	FY26E	FY27
EV/Sales	1.1	1.1	1.0	1.0	0.
EV/EBITDA	15.0	11.0	10.7	9.7	8.
Adjusted P/E	42.7	31.2	29.6	21.6	18.
P/BV	4.0	4.3	3.8	3.3	2.
DuPont Analysis					
Y/E 31 Mar (%)	FY23A	FY24A	FY25E	FY26E	FY27
Tax burden (Net profit/PBT)	78.2	67.9	73.3	74.9	74.
Interest burden (PBT/EBIT)	78.5	80.2	77.2	88.1	89.
EBIT margin (EBIT/Revenue)	4.9	7.0	6.9	7.3	7.
Asset turnover (Rev./Avg TA)	123.2	130.6	127.0	128.9	129.
Leverage (Avg TA/Avg Equity)	2.3	2.3	2.4	2.3	2.
Adjusted ROAE	8.6	11.4	11.8	14.4	15.
Ratio Analysis					
Y/E 31 Mar	FY23A	FY24A	FY25E	FY26E	FY27
YoY growth (%)					
Revenue	18.3	4.6	2.7	11.2	10.
EBITDA	(8.8)	34.0	3.2	13.4	13.
Adjusted EPS	(17.3)	37.0	5.3	36.9	19.
Profitability & Return ratios (%)	. ,				
EBITDA margin	7.6	9.8	9.8	10.0	10.
EBIT margin	4.9	7.0	6.9	7.3	7.
Adjusted profit margin	3.0	3.8	3.9	4.8	5.
Adjusted ROAE	8.6	11.4	11.8	14.4	15.
ROCE	9.8	16.4	15.2	16.3	17.
Working capital days (days)					
Receivables	40	47	47	47	4
Inventory	58	49	50	51	5
Payables	56	79	79	79	7
,					
Ratios (x)					
Gross asset turnover	2.2	1.9	1.8	1.9	2.
	2.2 1.1	1.9 1.0	1.8 1.1	1.9 1.2	
Gross asset turnover					2. 1. 6.

Adjusted debt/equity Source: Company, BOBCAPS Research | Note: TA = Total Assets

0.3

0.3

0.2 0.1 0.1



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

# Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited** Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051** SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025** Brand Name: **BOBCAPS** Trade Name: www.barodaetrade.com



Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


HOLD – Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

### Ratings and Target Price (3-year history): SOMANY CERAMICS (SOMC IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

#### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

#### **General disclaimers**

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

# SOMANY CERAMICS



The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or merchan banking or brokerage services from the subject company in the past 12 months.

#### Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construct this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

#### Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.